Maximus (NYSE:MMS) Stock Breaks Below 200-Day Moving Average - Here's Why

Maximus logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

  • Maximus shares fell below their 200-day moving average of $62.96, dipping to $61.16 before last trading at $62.00.
  • Fiscal Q4 adjusted earnings beat expectations at $2.11 per share versus roughly $1.85–$1.88 forecast, while revenue of $1.30 billion matched estimates but declined 1.3% year over year.
  • Recent business developments included the completion of the $660 million Agile Defense acquisition and fiscal 2027 revenue guidance of $5.5 billion–$5.7 billion, above analyst consensus of $5.4 billion.
  • Interested in Maximus? Here are five stocks we like better.

Shares of Maximus, Inc. (NYSE:MMS - Get Free Report) passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $62.96 and traded as low as $61.16. Maximus shares last traded at $62.00, with a volume of 845,916 shares traded.

Trending Headlines about Maximus

These are some of the MMS headlines that stood out recently:

  • Positive Sentiment: Fiscal Q4 adjusted earnings were $2.11 per share, above consensus estimates of about $1.85–$1.88 and up from $1.62 a year earlier. Maximus tops Q4 earnings estimates
  • Positive Sentiment: Maximus completed its $660 million acquisition of Agile Defense. The deal expands its national-security business, which is expected to approach 10% of company revenue. Agile Defense acquisition
  • Positive Sentiment: Fiscal 2027 revenue guidance of $5.5 billion to $5.7 billion exceeds the $5.4 billion analyst consensus. The company also reported an 89% contract recompete win rate in fiscal 2026. Long-term investor takeaways

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Maximus in a research report on Friday, November 13th. Wall Street Zen downgraded Maximus from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded Maximus from a "strong sell" rating to a "hold" rating in a research report on Thursday, October 1st. Two analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, Maximus currently has a consensus rating of "Hold".

Check Out Our Latest Stock Analysis on Maximus

Maximus Stock Performance

The company has a market capitalization of $3.25 billion, a PE ratio of 9.16 and a beta of 0.57. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 0.90. The business's fifty day moving average is $60.08 and its two-hundred day moving average is $62.96.

Maximus (NYSE:MMS - Get Free Report) last announced its quarterly earnings results on Thursday, November 19th. The health services provider reported $2.11 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.26. The firm had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.30 billion. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The business's revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.62 earnings per share. Maximus has set its FY 2027 guidance at 7.500-8.000 EPS. Equities research analysts predict that Maximus, Inc. will post 8.03 earnings per share for the current year.

Maximus Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be given a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Friday, November 13th. Maximus's dividend payout ratio is 19.50%.

Insider Transactions at Maximus

In other news, insider Michelle Link sold 3,208 shares of the business's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $54.23, for a total transaction of $173,969.84. Following the completion of the sale, the insider owned 13,881 shares of the company's stock, valued at $752,766.63. The trade was a 18.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.80% of the company's stock.

Institutional Trading of Maximus

A number of large investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in shares of Maximus by 45.1% during the third quarter. Bessemer Group Inc. now owns 515 shares of the health services provider's stock valued at $27,000 after purchasing an additional 160 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Maximus by 0.6% in the third quarter. Nisa Investment Advisors LLC now owns 31,919 shares of the health services provider's stock worth $1,698,000 after purchasing an additional 195 shares during the period. Allworth Financial LP lifted its holdings in Maximus by 60.8% in the third quarter. Allworth Financial LP now owns 645 shares of the health services provider's stock worth $35,000 after acquiring an additional 244 shares during the last quarter. Root Financial Partners LLC acquired a new position in Maximus in the third quarter valued at approximately $26,000. Finally, Covestor Ltd grew its holdings in shares of Maximus by 33.2% during the third quarter. Covestor Ltd now owns 2,199 shares of the health services provider's stock valued at $117,000 after purchasing an additional 548 shares during the last quarter. Institutional investors own 97.21% of the company's stock.

About Maximus

(Get Free Report)

Maximus, Inc. provides technology-enabled services to government agencies, helping them administer public programs and deliver services to residents. Its work includes managing contact centers, processing applications and eligibility determinations, conducting health assessments, and supporting appeals and other case-management functions. The company serves clients in the United States and internationally, including government agencies in the United Kingdom, Canada and Australia. Its services span health and human services programs as well as federal government operations, with technology and digital services supporting its program work.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Maximus Right Now?

Before you consider Maximus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.

While Maximus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines